As Curcumin does not selectively block microenvironment-derived IL-1β signaling, but also membrane-associated IL-1α signaling, which has been linked with antitumor immunity [16], the use of Curcumin or its dervatives should be considered carefully, depending on the therapeutic strategy and the individual tumor. This evidence concerns the gene IL1B and neoplasm.